Breakthrough T1D

• NCT07594145

  Collaborator, Phase 2, Not yet recruiting, 57 people, 18 May 2026

• NCT07284511

  Collaborator, Phase 2/3, Recruiting, 105 people, 16 Dec 2025

• NCT05696366

  Collaborator, Phase 1/2, Active, not recruiting, 24 people, 25 Jan 2023

• Islet Autoantibody Patterns Vary by Race and Ethnicity and Area Deprivation Index for Individuals at Risk for Type 1 Diabetes

  1 Oct 2026

• Natural history study of type 1 diabetes risk in adults (T1DRA): protocol for screening and follow-up of UK adults

  3-APF-2018-591-A-N, 29 Sept 2026

• Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study

  31 Aug 2026

• Lifespan Pancreas Morphology for Control Versus Type 2 Diabetes Using AI on Largescale Clinical Imaging

  1-INO-2023-1340-A-N, 20 Jan 2026

• Flow Cytometric Immune Profiling Enables Early Detection of Rejection in Islet Xenotransplantation

  1 Jan 2026

• Low Responsiveness of Macroencapsulated Human Islets Towards Glucose Challenge Despite Excellent Survival in Silicone-Based Oxygen-Delivering Devices

  31-2008-617, 31 Dec 2025

Sources: api.crossref.org, pubmed.ncbi.nlm.nih.gov

• Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial

  Grants or research support, 1 Oct 2026

• Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial

  Grants or research support, 30 Sept 2026

• Economic evaluation of NT-proBNP testing plus standard clinical assessment versus standard clinical assessment alone for the prevention of heart failure in older adults with type 2 diabetes

  Grants or research support, 28 Sept 2026

• Type 1 diabetes and cardiovascular medicine

  Grants or research support, 21 Sept 2026

• Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis

  Grants or research support, Board or leadership role, 7 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Semaglutide Use Along with Neural Network Fully Closed-Loop Systems Improves Time in Range (TIR) to 87% in Adults with Type 1 diabetes: In Silico Study

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Comparing Life's Essential 8 and Metabolic Syndrome with Risk of Microvascular Complications

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Association of Metabolic Risk Factors with Brain Health Outcomes in Persons with Type 1 Diabetes

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025